^
BIOMARKER:

KIT D820Y

i
Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
Entrez ID:
2ms
The in vitro experiments were conducted on a panel of cells harboring V600EBRAF, Q61RNRAS or D820YcKIT, either sensitive or with acquired resistance to the MAPK inhibitors dabrafenib, trametinib or dasatinib, respectively. The clinical part was performed on biopsies from patients with mutant BRAF melanoma and responsive or unresponsive to the BRAF inhibitor vemurafenib... Our data report a similar metabolic switch in melanoma cells with resistance to targeted therapies regardless of their mutation profile. This switch relies on increased glutaminolysis, OXPHOS, mitochondrial content and anti-oxidative properties. Patient samples allow to confirm cell line results and highlight new targets to suppress or delay the development of resistance mechanisms to MAPK inhibitors.
NRAS (Neuroblastoma RAS viral oncogene homolog) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
|
BRAF V600E • NRAS mutation • BRAF V600 • NRAS Q61R • NRAS Q61 • KIT D820Y
|
Mekinist (trametinib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib)
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our